Literature DB >> 10802655

A common polymorphism acts as an intragenic modifier of mutant p53 behaviour.

M C Marin1, C A Jost, L A Brooks, M S Irwin, J O'Nions, J A Tidy, N James, J M McGregor, C A Harwood, I G Yulug, K H Vousden, M J Allday, B Gusterson, S Ikawa, P W Hinds, T Crook, W G Kaelin.   

Abstract

The p73 protein, a homologue of the tumour-suppressor protein p53, can activate p53-responsive promoters and induce apoptosis in p53-deficient cells. Here we report that some tumour-derived p53 mutants can bind to and inactivate p73. The binding of such mutants is influenced by whether TP53 (encoding p53) codon 72, by virtue of a common polymorphism in the human population, encodes Arg or Pro. The ability of mutant p53 to bind p73, neutralize p73-induced apoptosis and transform cells in cooperation with EJ-Ras was enhanced when codon 72 encoded Arg. We found that the Arg-containing allele was preferentially mutated and retained in squamous cell tumours arising in Arg/Pro germline heterozygotes. Thus, inactivation of p53 family members may contribute to the biological properties of a subset of p53 mutants, and a polymorphic residue within p53 affects mutant behaviour.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10802655     DOI: 10.1038/75586

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  138 in total

1.  Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter.

Authors:  Takahito Nakagawa; Masato Takahashi; Toshinori Ozaki; Ken-ichi Watanabe Ki; Satoru Todo; Hiroyuki Mizuguchi; Takao Hayakawa; Akira Nakagawara
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

Review 2.  Single-nucleotide polymorphisms in the p53 signaling pathway.

Authors:  Lukasz F Grochola; Jorge Zeron-Medina; Sophie Mériaux; Gareth L Bond
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

3.  TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73.

Authors:  Kang Liu; Shiyun Ling; Weei-Chin Lin
Journal:  Mol Cell Biol       Date:  2011-09-19       Impact factor: 4.272

4.  Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants.

Authors:  Byron Hann; Allan Balmain
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  p53Arg72Pro polymorphism of tumour suppressor protein is associated with luminal narrowing after coronary stent placement.

Authors:  S Kojima; N Iwai; N Tago; K Ono; K Ohmi; G Tsujimoto; S Takagi; S Miyazaki; H Nonogi; Y Goto
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

6.  Mutant p53 cooperates with ETS2 to promote etoposide resistance.

Authors:  Phi M Do; Lakshman Varanasi; Songqing Fan; Chunyang Li; Iwona Kubacka; Virginia Newman; Krishna Chauhan; Silvano Rakeem Daniels; Maurizio Boccetta; Michael R Garrett; Runzhao Li; Luis A Martinez
Journal:  Genes Dev       Date:  2012-04-15       Impact factor: 11.361

7.  Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer.

Authors:  Marjun P Duldulao; Wendy Lee; Rebecca A Nelson; Joyce Ho; Maithao Le; Zhenbin Chen; Wenyan Li; Joseph Kim; Julio Garcia-Aguilar
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

8.  Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population.

Authors:  S Mitra; S Banerjee; C Misra; R K Singh; A Roy; A Sengupta; C K Panda; S Roychoudhury
Journal:  J Clin Pathol       Date:  2006-11-01       Impact factor: 3.411

9.  A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer.

Authors:  Sun Young Yi; Woon Jung Lee
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

Review 10.  The p53 family and programmed cell death.

Authors:  E C Pietsch; S M Sykes; S B McMahon; M E Murphy
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.